Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Spitz who wrote (207)	6/11/1998 7:58:00 PM
From: Gwolf	Read Replies (1) \| Respond to of 5402

Jim, remember this is a Biotech company.Until they actually get FDA approvals to market the product they are dependent on equity or debt funding. What we are waiting for is the announcement that they have received funding for their clinical trials on animals. This announcement is pending at anytime. This funding will come in the form of an equity investment from a financial backer with deep pockets. If they receive this funding then they will pay Battelle to start the testing and the show is on the road. The first trials are Phase 3 animal testing, from there they move into Phase 2 and Phase 3 human clinical trials. The initial funding will be for the animal trials. Baxter,lily,J&J and the like will be watching to see how that goes. They will need funding for the human trials but they probably will have the major drug companies falling all over themselves to help fund, partner or outright buy the company as soon as they see that the animal trials are going successfully. Considering that the company has already gone through this when they were a subsidiary of a Japanese company and received FDA approval this should be a foregone conclusion that everything will go well. The animal trials will only last 6 months so we should see what interest the majors have in a fairly short period of time. Gwolf